Keratoacanthoma
☆ Tamin'ny valin'ny Stiftung Warentest 2022 avy any Alemaina, ny fahafaham-pon'ny mpanjifa amin'ny ModelDerm dia ambany kely noho ny fifampidinihana telemedicine karama.
mahazatra Keratoacanthoma
References
Keratoacanthoma (KA) dia fivontosana hoditra matetika fantatra amin'ny fitomboany haingana sy mety hihemotra ho azy. Matetika izy io dia miseho amin'ny lehilahy antitra sy miloko tsara tarehy izay manana tantaran'ny fahasimban'ny masoandro. Raha ny fanesorana fandidiana amin'ny fampiasana excision na fandidiana mikrôgrafika Mohs no fitsaboana mahazatra, dia misy safidy fitsaboana hafa azo alaina.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Ny Keratoacanthoma (KA) dia fivontosana ambany ambany izay manomboka amin'ny fihary sasany ao amin'ny hoditra ary mitovitovy amin'ny squamous cell carcinoma (SCC) eo ambany mikraoskaopy. Mitohy ny adihevitra momba ny hoe tokony hosokajiana ho endrika SCC invasive ny KA.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) no karazana homamiadana faharoa fahita indrindra amin'ny olona, indrindra eo amin'ny olon-dehibe. Ny fandidiana dia matetika ampiasaina amin'ny fitsaboana cSCC, fa ho an'ny marary sasany izay tsy afaka fandidiana na misafidy ny tsy hanao, dia azo raisina ny safidy hafa toy ny fitsaboana intralesional. Efa nampiasaina ny fitsaboana nentim-paharazana (methotrexate or 5-fluorouracil) , saingy misy fikarohana mitohy momba ny fomba fiasa vaovao toy ny immunotherapy intralesional sy virotherapy oncolytic. Eto isika dia hijery fitsaboana intralesional isan-karazany ho an'ny cSCC, manomboka amin'ny fomba mahazatra ka hatramin'ny paikady faran'izay haingana.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Eo ambanin'ny mikraoskaopy, ny keratoacanthoma dia tena mitovy amin'ny carcinoma sela squamous. Na dia sokajian'ny manam-pahaizana manokana aza ny keratoacanthoma ho singa miavaka fa tsy homamiadana, manodidina ny 6% amin'ny keratoacanthoma klinika sy histôlôjika no mandroso mankany amin'ny kanseran'ny sela squamous mahery vaika sy mahery vaika.
○ Diagnose sy Fitsaboana
#Dermoscopy
#Skin biopsy